drugset / Trial / NCT07245953

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

NCT07245953 ↗

Phase 2 Active not recruiting 60 enrolled Suzhou HepaThera Biotech Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.

Timeline

Start
2025-11-05
Primary completion
2027-02
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HT-101 Unknown — Subcutaneous
Subject HT-102 Monoclonal antibody — Subcutaneous